Welcome to our dedicated page for Si-Bone news (Ticker: SIBN), a resource for investors and traders seeking the latest updates and insights on Si-Bone stock.
Si-Bone, Inc. (SIBN) is a leader in minimally invasive surgical solutions for sacroiliac joint disorders, pioneering orthopedic innovations since its founding. This news hub provides investors and healthcare professionals with essential updates on the company's progress in medical device development and market expansion.
Comprehensive SIBN Coverage: Access official press releases and third-party analysis covering regulatory milestones, quarterly earnings, product launches (including iFuse System updates), clinical trial results, and strategic partnerships. Our curated feed eliminates speculation to deliver actionable information about this NASDAQ-listed innovator.
Strategic Insights: Track SIBN's advancements in sacroiliac joint fusion technology alongside broader industry trends in orthopedic devices. Discover how patented titanium implants and FDA-cleared systems position the company within competitive medical sectors.
Bookmark this page for real-time updates on SIBN's financial performance, surgical innovation developments, and leadership in addressing underdiagnosed pelvic health conditions through clinically validated solutions.
SI-BONE (Nasdaq: SIBN) will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 2, 2025. Management will host a fireside chat at 9:00 a.m. Pacific / 12:00 p.m. Eastern.
Investors can register to listen and access a live audio webcast via the company’s Investors website. The webcast will be archived and available for replay for at least 90 days after the event.
SI-BONE (Nasdaq: SIBN) reported Q3 2025 results with $48.7M worldwide revenue, up 20.6% year-over-year, and $46.4M U.S. revenue, up 21.2%. Gross margin improved to 79.8% (up 75 bps). Net loss narrowed to $4.6M (‑$0.11/share) and adjusted EBITDA was positive $2.3M. The company generated $2.3M of operating cash flow and held $145.7M in cash and equivalents.
Operationally, active U.S. physicians rose 27% to 1,530 and trailing 12-month average revenue per territory grew 16%. Effective Oct 1, 2025, procedures using iFuse TORQ TNT qualify for an NTAP of over $4,100. SI-BONE raised full-year 2025 revenue guidance to $198M–$200M and expects full-year gross margin of ~79.5%.
SI-BONE (Nasdaq: SIBN) reported second-quarter 2025 results with worldwide revenue of $48.6M (+21.7% YoY) and U.S. revenue of $46.4M (+22.8% YoY). Gross margin was 79.8% and adjusted EBITDA turned positive at $1.0M, while net loss improved to $6.2M (‑31.2%). Cash and equivalents totaled $145.5M with $1.1M net cash generated in the quarter. Operationally, active U.S. physicians grew ~25% to 1,440 and trailing 12‑month average revenue per territory rose ~23%. Fiscal 2025 revenue guidance was updated to $195M–$198M (~17%–18% growth) with expected full‑year positive adjusted EBITDA.
SI-BONE (Nasdaq: SIBN) will report its third quarter 2025 financial results after market close on Monday, November 10, 2025.
Management will host a conference call on that day at 1:30 p.m. PT / 4:30 p.m. ET. Investors can register for the live call via the provided media-server link and listen to the live webcast in the Investors section of the company website. The webcast will be archived and available for replay for at least 90 days after the event.
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The company's management will conduct a fireside chat on September 9, 2025, at 4:00 AM PT / 7:00 AM ET.
Investors can access the presentation through registration, and a live webcast will be available on SI-BONE's investor relations website. The webcast recording will remain accessible for at least 90 days following the event.
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference in Boston. The company's management will conduct a fireside chat on August 12, 2025, at 3:00 PM ET.
Investors can access the presentation through a webcast by registering online, and the live audio will be available on the company's website investor section. The webcast recording will remain accessible for replay for at least 90 days following the event.
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has scheduled its second quarter 2025 financial results announcement for August 4, 2025 after market close.
The company will host a conference call at 1:30 PM PT / 4:30 PM ET. Investors can access the call through registration and listen to the live webcast on SI-BONE's investor relations website. The webcast recording will remain available for replay for at least 90 days following the event.
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, announced its participation in the Goldman Sachs 46th Global Healthcare Conference in Miami Beach. The company's management will conduct a fireside chat on June 10, 2025, at 8:20 AM PT/11:20 AM ET. Investors can access the live webcast through registration and the company's website. The webcast recording will be available for replay on SI-BONE's investor relations page for at least 90 days following the event.
SI-BONE Inc (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has announced its participation in the 2025 BofA Securities Healthcare Conference in Las Vegas. The company's management will conduct a fireside chat on May 13, 2025, at 8:40 AM PT/11:40 AM ET. Investors can access the live webcast through a registration link or the company's website investor section. The webcast recording will remain available for replay for at least 90 days following the event.
FAQ
What is the current stock price of Si-Bone (SIBN)?
What is the market cap of Si-Bone (SIBN)?
